{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:07:05Z","timestamp":1740136025187,"version":"3.37.3"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study aimed to develop a suitable osteomyelitis model for pharmacokinetic\/pharmacodynamic (PK\/PD) evaluation and to investigate the target PK\/PD values of vancomycin and tedizolid against methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An osteomyelitis model was established by implanting an MRSA-exposed sterilized suture in the tibia of normal mice and mice with cyclophosphamide-induced neutropenia. The suitability of the osteomyelitis mouse model for PK\/PD evaluation was assessed using vancomycin as an indicator. The target PK\/PD values for tedizolid were determined using this model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>In neutropenic mice, to achieve a static effect and 1 log10 kill against MRSA, the ratios of the area under the free drug concentration\u2013time curve for 24 h to the minimum inhibitory concentration (fAUC24\/MIC) of vancomycin were 91.29 and 430.03, respectively, confirming the validity of the osteomyelitis model for PK\/PD evaluation. In immunocompetent mice, the target fAUC24\/MIC values of tedizolid for achieving a static effect and 1 log10 kill against MRSA were 2.40 and 49.20, respectively. Additionally, only a 0.28 log10 kill was achieved in neutropenic mice with 20 times the human equivalent dose of tedizolid.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In patients with restored immunity, tedizolid can potentially be used as an alternative to intravenous vancomycin therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jpp\/rgae124","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T22:28:21Z","timestamp":1730932101000},"page":"291-298","source":"Crossref","is-referenced-by-count":0,"title":["Development of a pharmacokinetic\/pharmacodynamic evaluation model for osteomyelitis and usefulness of tedizolid as an alternative to vancomycin against MRSA osteomyelitis"],"prefix":"10.1093","volume":"77","author":[{"given":"Xiaoxi","family":"Liu","sequence":"first","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University , 1-5-30 Shiba koen, Minato-ku, Tokyo 105-8512 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5934-0670","authenticated-orcid":false,"given":"Yuki","family":"Enoki","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University , 1-5-30 Shiba koen, Minato-ku, Tokyo 105-8512 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University , 1-5-30 Shiba koen, Minato-ku, Tokyo 105-8512 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University , 1-5-30 Shiba koen, Minato-ku, Tokyo 105-8512 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"2025020305562852800_CIT0001","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","article-title":"Osteomyelitis","volume":"364","author":"Lew","year":"2004","journal-title":"Lancet"},{"key":"2025020305562852800_CIT0002","doi-asserted-by":"publisher","first-page":"059","DOI":"10.1055\/s-0029-1214158","article-title":"Osteomyelitis of the long bones","volume":"23","author":"Calhoun","year":"2009","journal-title":"Semin Plast Surg"},{"key":"2025020305562852800_CIT0003","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"2025020305562852800_CIT0004","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"2025020305562852800_CIT0005","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/ajhp\/zxaa244","article-title":"Intraperitoneal vancomycin treatment of multifocal methicillin-resistant Staphylococcus aureus osteomyelitis in a patient on peritoneal dialysis","volume":"77","author":"Abid","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2025020305562852800_CIT0006","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/cid\/cir124","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025020305562852800_CIT0007","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.clinthera.2013.05.008","article-title":"A stewardship program\u2019s retrospective evaluation of vancomycin AUC24\/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis","volume":"35","author":"Gawronski","year":"2013","journal-title":"Clin Ther"},{"key":"2025020305562852800_CIT0008","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s15010-004-3029-9","article-title":"Linezolid in the treatment of osteomyelitis: results of compassionate use experience","volume":"32","author":"Rayner","year":"2004","journal-title":"Infection"},{"key":"2025020305562852800_CIT0009","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.clinthera.2006.08.001","article-title":"Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study","volume":"28","author":"Senneville","year":"2006","journal-title":"Clin Ther"},{"key":"2025020305562852800_CIT0010","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/ce.s33430","article-title":"An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy","volume":"131","author":"Watkins","year":"2012","journal-title":"Core Evid"},{"key":"2025020305562852800_CIT0011","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1248\/bpb.b22-00276","article-title":"Target therapeutic ranges of anti-MRSA drugs, linezolid, tedizolid and daptomycin, and the necessity of TDM","volume":"45","author":"Matsumoto","year":"2022","journal-title":"Biol Pharm Bull"},{"key":"2025020305562852800_CIT0012","doi-asserted-by":"publisher","first-page":"7198","DOI":"10.1128\/AAC.03509-14","article-title":"Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials","volume":"58","author":"Lodise","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020305562852800_CIT0013","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/00003086-199903000-00008","article-title":"Antimicrobial treatment of chronic osteomyelitis","volume":"360","author":"Mader","year":"1999","journal-title":"Clin Orthop Relat Res"},{"key":"2025020305562852800_CIT0014","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3238\/arztebl.2012.0257","article-title":"Treatment algorithms for chronic osteomyelitis","volume":"109","author":"Walter","year":"2012","journal-title":"Dtsch Arztebl Int"},{"key":"2025020305562852800_CIT0015","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1248\/bpb.b22-00361","article-title":"Exploring the factors affecting the transferability of vancomycin to cerebrospinal fluid in postoperative neurosurgical patients with bacterial meningitis","volume":"45","author":"Ichinose","year":"2022","journal-title":"Biol Pharm Bull"},{"key":"2025020305562852800_CIT0016","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11095-022-03425-5","article-title":"Differences in pharmacokinetic\/pharmacodynamic parameters of tedizolid against VRE and MRSA","volume":"40","author":"Liu","year":"2023","journal-title":"Pharm Res"},{"key":"2025020305562852800_CIT0017","first-page":"77","article-title":"Study on experimental osteomyelitis: suppressive activity of macrolide on cytokine (IL-6,IL-1\u03b2)","author":"Magara","year":"1997","journal-title":"Kobe Univ Repos"},{"key":"2025020305562852800_CIT0018","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1471-2334-6-55","article-title":"Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases","volume":"6","author":"Zuluaga","year":"2006","journal-title":"BMC Infect Dis"},{"key":"2025020305562852800_CIT0019","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.clinthera.2016.06.014","article-title":"Pharmacokinetics and safety of tedizolid after single and multiple intravenous\/oral sequential administrations in healthy Chinese subjects","volume":"38","author":"Chen","year":"2016","journal-title":"Clin Ther"},{"key":"2025020305562852800_CIT0020","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/j.clinthera.2017.08.002","article-title":"Pharmacokinetics, safety, and tolerability of tedizolid phosphate after single-dose administration in healthy Korean male subjects","volume":"39","author":"Kim","year":"2017","journal-title":"Clin Ther"},{"key":"2025020305562852800_CIT0021","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1124\/dmd.113.056697","article-title":"Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate","volume":"42","author":"Ong","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"2025020305562852800_CIT0022","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2025020305562852800_CIT0023","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/jcph.175","article-title":"Unbound fraction of vancomycin in intensive care unit patients","volume":"54","author":"Kees","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"2025020305562852800_CIT0024","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ijantimicag.2009.08.005","article-title":"Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections","volume":"34","author":"Berthoin","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"2025020305562852800_CIT0025","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ijantimicag.2013.01.009","article-title":"Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects","volume":"41","author":"Ampe","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2025020305562852800_CIT0026","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1128\/AAC.01485-12","article-title":"Vancomycin AUC\/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia","volume":"57","author":"Holmes","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020305562852800_CIT0027","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/pharmaceutics14030489","article-title":"Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"14","author":"Matsumoto","year":"2022","journal-title":"Pharmaceutics"},{"key":"2025020305562852800_CIT0028","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2025020305562852800_CIT0029","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-021-05858-6","article-title":"The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing","volume":"21","author":"Tsutsuura","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2025020305562852800_CIT0030","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1128\/AAC.01565-10","article-title":"In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model","volume":"55","author":"Louie","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020305562852800_CIT0031","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ijid.2021.04.014","article-title":"Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017\u20132019)","volume":"107","author":"Carvalhaes","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2025020305562852800_CIT0032","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/jac\/25.4.679","article-title":"Nephrotoxicity of vancomycin, alone and with an aminoglycoside","volume":"25","author":"Rybak","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"2025020305562852800_CIT0033","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1345\/aph.1P583","article-title":"Vancomycin-induced neutropenia: is it dose- or duration-related","volume":"45","author":"Black","year":"2011","journal-title":"Ann Pharmacother"},{"key":"2025020305562852800_CIT0034","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/jor.20003","article-title":"IntracellularStaphylococcus aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis","volume":"24","author":"Ellington","year":"2006","journal-title":"J Orthop Res"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/77\/2\/291\/60456291\/rgae124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/77\/2\/291\/60456291\/rgae124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T05:56:36Z","timestamp":1738562196000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/77\/2\/291\/7879609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,11,6]]},"published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgae124","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"type":"print","value":"0022-3573"},{"type":"electronic","value":"2042-7158"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,11,6]]}}}